25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS)
09.09.2009 - 12.09.2009
Please select a day:
09.09.2009
10.09.2009
11.09.2009
12.09.2009
Search
Personal programme
Please enter your email address here in order to bring up your personal programme



Home - 11.09.2009


Friday, September 11, 2009
15:30 - 17:00

Poster topic 37

Late breaking news

Oral teriflunomide or placebo added to interferon beta for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results
   P 878
M. Freedman, J.S. Wolinsky, W.J. Byrnes, C. Confavreux, G. Comi, G. Frangin, L. Kappos, T. Olsson, A. Miller, P.W. O’Connor for the Teriflunomide Multiple Sclerosis Trial Group
Astroglia pathology in early multiple sclerosis
   P 879
F.B. König, A. Löscher, I. Metz, S. Müller, C. Lucchinetti, W. Brück (Göttingen, Berlin, DE; Rochester, US)
TH1 and TH17 pathways determine responsiveness to IFN-beta treatment of autoimmune neuro-inflammation
   P 880
R.C. Axtell, B.A. de Jong, R. Bhat, L. Katz, C. Raman, L. Steinman (Stanford, US)
Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis – results of the MUSEC study
   P 881
J. Zajicek, M. Reif, M. Schnelle on behalf of the UK MUSEC Study Investigators
Acute treatment related neurotoxicity in secondary progressive multiple sclerosis
   P 882
A. Petzold, T. Mondria, J. Kuhle, J. Cornelissen, M. Rocca, P. te Boekhorst, B. Lowenberg, G. Giovannoni, M. Filippi, L. Kappos, R.Q. Hintzen (London, UK; Rotterdam, NL; Basel, CH; Milan, IT)
Evaluation of natalizumab treatment on the presence of JC virus in blood and urine from multiple sclerosis patients
   P 883
R.A. Rudick, C.H. Polman, P.W. O’Connor, A.D. Goodman, S. Ray, C. Ryschkewitsch, S. Jurgensen, S. Goelz, F. Forrestal, L. Gorelik, M.A. Panzara, A.W. Sandrock, E.O. Major (Cleveland, US; Amsterdam, NL; Toronto, CA; Rochester, Cambridge, Bethesda, US)
Fatal progressive multifocal leukoencephalopathy associated with efalizumab therapy: Insights into the role of leukointegrin aLb2 in JC virus control
   P 884
N. Schwab, J.C. Ulzheimer, R.J. Fox, Y.H. Huang, T. Schneider-Hohendorf, M-P. Stenner, W. Welch, B.C. Kieseier, C.M. Monoranu, S.M. Staugaitis, W. Brück, K.V. Toyka, R.M. Ransohoff, H. Wiendl (Wurzburg, DE; Cleveland, US; Düsseldorf, Gottingen, DE)
PLS models discriminate types of MS from spectroscopic analysis of plasma and urine
   P 885
A.M. Dickens, D.C. Anthony, T.D.W. Claridge, S. Mardiguian, A. Cavay, B.G. Davis, J.L. Griffin, S.J. Campbell, J. Palace, N.R. Sibson (Oxford, Cambridge, UK)
Oral fingolimod (FTY720) therapy reduces blood brain barrier breakdown, microglial activation, and leukocyte recruitment in a focal DTH model of multiple sclerosis
   P 886
D.C. Anthony, N.R. Sibson, P. Losey, D. Piani, D. Leppert (Oxford, UK; Basel, CH)
Increased T cell immunity against aquaporin-4 in neuromyelitis optica
   P 887
N. Matsuya, M. Komori, K. Nomura, H. Matsuo, T. Kondo (Nagasaki, Kyoto, Saitama, Osaka, JP)
The anti-viral cytokine Interferon-alpha is expressed in acute MS lesions and associated with the presence of Epstein-Barr virus infection
   P 888
J. Tzartos, G. Khan, A. Vossenkaemper, T. Meager, E. Sefia, M. Clemens, G. Giovannoni, M. Esiri, U. Meier (Oxford, UK; Al Ain, AE; London, Potters Bar, UK)
Non invasive surveillance of JCV reactivation in blood and urine from natalizumab treated MS patients, blood donors and immunocompromised patients identifies two PML cases in HIV and congenital immunodeficiency patients
   P 889
O.E. Varnier, J.L. McDermott, C.G. Giacomazzi, M. Perotti, I. Martini, D. Rolla, G. Cannella, A. Bacigalupo, F. Indiveri, C. Viscoli, E. Capello, A. Uccelli, G.L. Mancardi (Genoa, IT)
Alemtuzumab treatment benefit is durable: primary efficacy outcomes of CAMMS223 at 4 years
   P 890
A. Coles on behalf of the CAMMS223 Study Group